Tazemetostat + talazoparib for metastatic castration-resistant #ProstateCancer. @AtishChoudhury @DanaFarber joins Evan Yu, MD @fredhutch to discuss a first-in-human trial combining EZH2 and PARP inhibition in #mCRPC. #WatchNow on UroToday > https://t.co/HWkvCMX43q

Truly a joy to participate in @TheJimmyFund Radio-Telethon with Kevin! https://t.co/HO4I1kvXJW

I am so appreciative that my dear patient Kevin was willing to come out to Fenway Park for the @WEEI / @NESN @TheJimmyFund Radio-Telethon to raise awareness around prostate cancer and to support research at @DanaFarber @DanaFarber_GU. #KCANCER https://t.co/HO4I1kvXJW

🇬🇷 Fantastic dinner at Ammos restaurant after a phenomenal Friday at #Athensmeeting organized by @PGrivasMDPhD with @Prof_Nick_James, @bergsa83, @drjefstathiou, @DrTFriedlander, @easterho. Thank you for the wonderful hospitality!

Thank you @urotoday and @RKSayyid for this comprehensive writeup of my talk. ADT-free strategies certainly warrant further study, but novel treatments also bring the opportunity to explore multimodality strategies with curative intent. @DanaFarber_GU @CaPsurvivorship

Thank you to the discussant Rahul Aggarwal and @jordanciuro for highlighting A-DREAM for treatment interruption for pts with PSA < 0.2 after 18-24 mo of ADT+ARPI, with primary endpoint of 18 months treatment-free with testosterone recovery. @DanaFarber_GU @bergsa83 @ALLIANCE_org

📢 #ASCO25 | 3:00 PM–4:30 PM Clinical Science Symposium | Radioligand Therapies Unplugged: Is It Time to Break up With ADT? | Atish D. Choudhury dissects BULLSEYE Ph III insights on ^177Lu‑PSMA‑617 in oHSPC—delaying ADT, QoL benefits, and safety considerations. By our

The whole team at the Gelb Center for Translational Research @DanaFarber_GU are so proud of Ilana's poster presentation and many other achievements!

Prostate cancer at #ASCO25: Talazoparib + tazemetostat showed expected bone marrow suppression & limited benefit in pre-treated, biomarker-unselected patients. Research underway to ID those most likely to respond. @AtishChoudhury @DanaFarber_GU

We are so honored to have you join us, @FaltasLab, and we are really looking forward to your talk on this fascinating topic!

🗣️Prostate Cancer Rapid Oral Abstracts #GU25 Dr Michael Schweizer presenting Ab138 "Mevrometostat (PF-06821497), an (EZH2) inhibitor, in combination with ENZA in patients with (mCRPC): A randomized dose-expansion study." N = 81 mCRPC prior ABI, <1 chemo (~45%), PD per PCWG3

🗣️Prostate Cancer Rapid Oral Abstracts #GU25 Dr Abdenour Nabid presenting Ab310 "Impact of testosterone recovery after androgen deprivation therapy on overall survival in patients with high-risk prostate cancer: Long-term data from a phase III trial." N = 630 RT + ADT 18 mo

So proud for Autumn Gagnon to have the opportunity to present her work on testosterone suppression and recovery with abiraterone after early LHRH-A discontinuation. We are excited that she has chosen to apply to medical school! @DanaFarber_GU

Thank you @DanaFarberNews for highlighting this work conducted by talented CRC Autumn Gagnon demonstrating in pts treated with defined course ADT+abi that early d/c of LHRH-A allowed ongoing castrate T with abi mono but earlier and more reliable T recovery after stopping.

Thank you @DanaFarber for this recognition, and to @DrChoueiri for your guidance and advocacy. I appreciate all the support from mentors, collaborators, colleagues, research staff, and trial participants as we try to continue to advance care of patients with GU cancers.

Now activated! CLEARED will enroll pts with high-risk localized, lymph node-positive or low volume HSPC (planned for treatment interruption) to receive 2 years of relugolix+darolutamide for PK studies of the combo and to assess T recovery after completion.

It's not too late to join our contribute to our team at https://t.co/TeiMwkcfB0 to support Movember's efforts towards prostate cancer, testicular cancer and mental health research and resources.

See you at Kings Back Bay on Monday 11/25/24 from 6-10 pm for BellissiMO’s @Movember Fundraising Finale. There will be food, karaoke, and celebration! @DrPaulNguyen @RickLee6 @AFeldmanMD @loreleimucci @mishabeltran @MA_Preston @qdtrinh @sophia_kamran @BoyajianRichard

On multivariable analysis, duration of treatment >=12 months was independently associated with cPFS after T recovery, provocatively suggesting that prolonged systemic therapy could sterilize (or render permanently dormant) micrometastatic disease and lead to "cure" in a subset.

Congratulations to @PrafulRavi1 and colleagues for presenting data from our cohort. Of note, 3-year cPFS after T recovery for patients receiving "total therapy" was 51% for those who received >=12 mo ADT, and the swimmer's plot shows patients out to > 10 years after T recovery.